CHAPTER 354
SB 402 - FINAL VERSION
03/07/2024 0825s
23May2024... 1810h
06/13/2024 2350EBA
2024 SESSION
24-2961
11/05
SENATE BILL 402
SPONSORS: Sen. Birdsell, Dist 19
COMMITTEE: Health and Human Services
─────────────────────────────────────────────────────────────────
AMENDED ANALYSIS
This bill allows pharmacists to administer influenza, COVID-19, and other FDA licensed vaccines without explicit approval from the general court.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
03/07/2024 0825s
23May2024... 1810h
06/13/2024 2350EBA 24-2961
11/05
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Twenty Four
Be it Enacted by the Senate and House of Representatives in General Court convened:
Amend section 1 of the bill by replacing line 1 with the following:
354:1 Pharmacist Administration of Vaccines. Amend RSA 318:16-b to read as follows:
318:16-b Pharmacist Administration of Vaccines.
I. A pharmacist, pharmacy intern, licensed advanced pharmacy technician, or certified pharmacy technician, under the supervision of an on-site immunizing pharmacist may administer influenza and a COVID-19 vaccine, if available, to the general public.
II. A pharmacist, pharmacy intern, or licensed advanced pharmacy technician, under the supervision of an on-site immunizing pharmacist may administer [haemophilus influenza, hepatitis A, hepatitis B, hepatitis A and B, human papillomavirus, meningococcal, pneumococcal, tetanus and diphtheria, varicella, zoster, RSV (respiratory syncytial virus), MMR (measles, mumps, and rubella), and Tdap (tetanus, diphtheria and pertussis) vaccines, which have been approved by the Food and Drug Administration] vaccines licensed by the United States Food and Drug Administration that are recommended by the United States Centers for Disease Control and Prevention Advisory Committee on Immunization Practices, or successor organization, to individuals 18 years of age or older as ordered by an immunizing pharmacist.
III. The pharmacist, pharmacy intern, licensed advanced pharmacy technician, or certified pharmacy technician who administers the vaccine shall:
[I.] (a) Hold a current license to practice as a pharmacist, be registered as a pharmacy intern under RSA 318:15-b in New Hampshire, or be licensed as a licensed advanced pharmacy technician under RSA 318:15-c, or be a certified pharmacy technician and registered with the board pursuant to RSA 318:15-a.
[II.] (b) Possess at least $1,000,000 of professional liability insurance coverage.
[III.] (c) In order to administer vaccines, have completed training specific to administration of the respective vaccines that includes programs approved by the Accreditation Council for Pharmacy Education (ACPE) or curriculum-based programs from an ACPE-accredited college of pharmacy or state or local health department programs or programs recognized by the board. This training shall include hands-on injection technique and the recognition and treatment of emergency reactions to vaccinations.
[IV.] (d) Have a current certificate in basic cardiopulmonary resuscitation.
[V.] (e) Provide to the board evidence of compliance with [paragraphs I- IV] subparagraphs (a)-(d).
[VI.] (f) Provide notice to the primary care provider, when designated by the patient, of the administration of any vaccine.
[VII.] (g) Record the vaccination in the state vaccine registry in accordance with RSA 141-C:20-f and/or when required by state and federal law and maintain a record of the vaccination as required by state and federal law.
[VIII.] (h) Submit reports of any adverse reactions following vaccination to the Centers for Disease Control (CDC) Vaccine Adverse Event Reporting System (VAERS).
[IX.] (i) Review the vaccine registry or other vaccination records before administering the vaccination.
354:2 Effective Date. This act shall take effect 60 days after its passage.
Approved: August 02, 2024
Effective Date: October 01, 2024
| Date | Amendment |
|---|---|
| Feb. 21, 2024 | 2024-0825s |
| May 15, 2024 | 2024-1976h |
| May 15, 2024 | 2024-1810h |
| May 20, 2024 | 2024-2067h |
| July 11, 2024 | 2024-2350EBA |
| Date | Body | Type |
|---|---|---|
| Feb. 14, 2024 | Senate | Hearing |
| Feb. 14, 2024 | Senate | Hearing |
| March 7, 2024 | Senate | Floor Vote |
| March 7, 2024 | Senate | Floor Vote |
| April 25, 2024 | House | Hearing |
| May 1, 2024 | House | Exec Session |
| May 8, 2024 | House | Exec Session |
| May 15, 2024 | House | Exec Session |
| May 8, 2024 | House | Floor Vote |
Aug. 7, 2024: Signed by the Governor on 08/02/2024; Chapter 354; Effective 10/01/2024
July 18, 2024: Enrolled Adopted, VV, (In recess 06/13/2024); SJ 18
July 23, 2024: Enrolled (in recess of) 06/13/2024 HJ 16 P. 56
July 18, 2024: Enrolled Adopted, VV, (In recess 06/13/2024); SJ 18
July 18, 2024: Enrolled Adopted, VV, (In recess 06/13/2024); SJ 18
July 23, 2024: Enrolled (in recess of) 06/13/2024 HJ 16
July 11, 2024: Enrolled Bill Amendment # 2024-2350e Adopted, VV, (In recess of 06/13/2024); SJ 18
July 23, 2024: Enrolled Bill Amendment # 2024-2350e: AA VV (in recess of) 06/13/2024 HJ 16 P. 51
July 11, 2024: Enrolled Bill Amendment # 2024-2350e Adopted, VV, (In recess of 06/13/2024); SJ 18
May 30, 2024: Sen. Birdsell Moved to Concur with the House Amendment, MA, VV; 05/30/2024; SJ 16
May 23, 2024: Ought to Pass with Amendment 2024-1810h: MA DV 231-135 05/23/2024 HJ 14 P. 115
May 23, 2024: FLAM # 2024-2067h (NT) (Rep. Layon): AF DV 177-185 05/23/2024 HJ 14 P. 114
May 23, 2024: Amendment # 2024-1810h: AA VV 05/23/2024 HJ 14 P. 113
May 15, 2024: Minority Committee Report: Inexpedient to Legislate
May 15, 2024: Majority Committee Report: Ought to Pass with Amendment # 2024-1810h 05/08/2024 (Vote 14-6; RC) HC 20 P. 26
May 8, 2024: ==CANCELLED== Executive Session: 05/15/2024 01:00 pm LOB 205-207
May 2, 2024: ==CONTINUED== Executive Session: 05/08/2024 11:00 am LOB 205-207
April 24, 2024: ==RECESSED== Executive Session: 05/01/2024 10:00 am LOB 210-211
April 17, 2024: Public Hearing: 04/25/2024 01:45 pm LOB 206-208
March 12, 2024: Introduced 03/07/2024 and referred to Health, Human Services and Elderly Affairs HJ 7 P. 110
March 7, 2024: Ought to Pass with Amendment 2024-0825s, MA, VV; OT3rdg; 03/07/2024; SJ 6
March 7, 2024: Committee Amendment # 2024-0825s, AA, VV; 03/07/2024; SJ 6
Feb. 21, 2024: Committee Report: Ought to Pass with Amendment # 2024-0825s, 03/07/2024; Vote 5-0; CC; SC 9
Feb. 21, 2024: Committee Report: Ought to Pass with Amendment # 2024-0825s, 03/07/2024; Vote 5-0; CC; SC 9
March 7, 2024: Committee Amendment # 2024-0825s, AA, VV; 03/07/2024; SJ 6
Feb. 8, 2024: Hearing: 02/14/2024, Room 101, LOB, 10:00 am; SC 7
Feb. 12, 2024: ==ROOM CHANGE== Hearing: 02/14/2024, Room 100, SH, 10:00 am; ; SC 7
Dec. 12, 2023: To Be Introduced 01/03/2024 and Referred to Health and Human Services; SJ 1